MiNK Therapeutics announced it will present Phase II clinical trial data at AACR 2026 on its allo-iNKT cell therapy agenT-797 combined with botensilimab and balstilimab for PD-1 refractory gastroesophageal cancer. This study addresses a critical need for patients resistant to checkpoint inhibitors by exploring a novel immune therapy that bridges innate and adaptive immunity to potentially improve treatment durability. The data are expected to provide insights on immune system reprogramming and treatment sequencing to enhance outcomes in difficult-to-treat cancers. The presentation will take place on April 20, 2026, at the AACR Annual Meeting in San Diego.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
